Home > Insider Trading > Filing (0001127602-15-006015)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
884731	Ariad Pharmaceuticals Inc	ARIA	Biological Products, (No Disgnostic Substances) (2836)	223106987

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
932052	D M J Harvey Berger	C/O Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge MA 02139	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-02-11	12,500	$6.77	1,851,786	No	4	P	Indirect	Ocean Capital Partners, Llc
Common Stock	Acquisiton	2015-02-12	12,500	$6.90	1,864,286	No	4	P	Indirect	Ocean Capital Partners, Llc

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Ocean Capital Partners, Llc
No	4	P	Indirect	Ocean Capital Partners, Llc

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,250,654	Direct
Common Stock	246,054	Indirect	Daughter
Common Stock	248,745	Indirect	Daughter
Common Stock	245,251	Indirect	Wife

Footnotes

Shares were aquired pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.73 to $6.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the range set forth in this footnote.
The reporting person is a managing member of this LLC.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.84 to $6.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the range set forth in this footnote.